This acquisition is another step in Getinge Life Science strategic journey to further expand our presence in the biopharma segment
Without the injections that I get every 6-8 weeks, I would have been completely blind.
It is gratifying that we, in the quarter, received premarket approval (PMA) in the US from the FDA for the iCast™ stent system for the treatment of patients with iliac arterial occlusive disease.
The idea is to connect the artificial placenta to the baby's umbilical cord via cannulas. During the critical first weeks of life, it can provide natural support for breathing, feeding and blood purification.
As experts on the first step in the surgical instrument reprocessing flow, we help prevent cross-contamination and healthcare acquired infections.
Together with our wonderful colleagues, we build anesthesia machines and ventilators that help medical staff save lives, which is amazing. We feel like heroes and we're lucky to be part of this every day.
Sustainability is not a separate activity. Being a medtech company, it is ingrained in everything we do. Our passion for life extends beyond the immediate impact of our products and we strive to be an agent of positive change, both for the people in this world and for the planet itself.
We continuously grow through relevant acquisitions to expand our offering. We also see, perhaps more than ever, that digital advances in healthcare are helping more patients be treated more safely, while the work environment is positively impacted and costs kept under control. We have world-leading solutions that contribute to this, and more are on the way,
I am proud of how we have kept innovating the products over the years to offer hospitals safe, efficient and sustainable high-quality solutions for sterile reprocessing of medical instruments.
We are pleased that the iCast™ stent system is approved in the United States for use in iliac arteries to benefit an even greater number of patients
I found the range of Getinge’s portfolio exciting with lots of opportunities to learn. I also liked the fact that Getinge is serious about lowering its environmental impact and contributing to a more sustainable world. It was a good cultural fit for me.
With the addition of Ultra Clean’s expertise and technology, we significantly expand our offering to sterile reprocessing departments in North America, which now contains a complete range of process equipment, consumables and IT solutions.
By using EcoDesign, we reduce the environmental impact of our products throughout their life cycles.
I love being part of the process of creating tomorrow’s acute care therapy solutions together with a big and passionate team.
Thanks to our wide range of equipment and imaging solutions from Siemens Healthineers, we were able to create an installation that balanced the customer’s clinical needs and the required functionality of the imaging equipment.
For 2023 we are expecting a weaker first half of the year as a result of continuing challenging comparative figures for significant parts of Acute Care Therapies and Life Science, whereas the second half of the year is expected to be stronger. This will result in healthy growth for us in the second half of the year and an anticipated organic sales growth of 2-5% for the full-year.
With our new customized PILOT Patient Transfer System and Magnus operating table from Getinge, we never have to move the patient from one table to another. They are completely stable throughout the procedure which mitigates risks, ensures the precision of our treatment and supports a smooth workflow.
It starts with a reel of thread and finishes with a high-quality medical device, a vascular graft used in the treatment of hundreds of patients per day. That’s how I summarize my days; by thinking of how many potential patients each newly created solution can reach.
Lung-protection challenges come in many shapes and sizes. That is why Servo-c is designed for safe, easy and efficient use that enable personalized respiratory treatments.
We are very happy to help kinderherzen in their important work to provide a brighter future for these children.
Livit Flex brings nearly half a century of expertise together with the latest technologies to deliver an intuitive and easily configurable bioprocess controller that fits any R&D application.
I’m very happy to see Getinge and BNP Paribas Leasing Solutions join forces to offer sustainable, innovative and competitive finance solutions to healthcare professionals across Europe. I am confident that our combined expertise together with the structural shift towards sustainable usage-based models will make this partnership a success.
With this initiative, our employees will not have to choose between family or work, but manage both when their family needs them the most.
With this initiative our employees will not have to choose between family or work, but manage both, when their family needs them the most.
The purpose of our ethics and compliance work is to ensure that the decisions we make today are well informed, balanced and can withhold scrutiny also in the future.
Our bioreactors play an important role in the development of cellular agriculture. By growing the cells in a closed environment, the bioreactor, you ensure that meat or fish is cultivated in a clean and controlled manner. This is critical for optimal growth of cells and therefore the development of healthy and nutritious food.
I am amazed about the level of details and how real it feels.
We manufacture a broad line of collagen coated knitted and woven vascular grafts and patches. It’s amazing to see the process, which starts with a reel of thread and finishes with a high-quality medical device for patients to support crucial treatments.
The American Heart Association came up with a brilliant way of fostering collaboration among experts, and we want to support that. The data collected will provide high-quality evidence and important best practice treatments for health care stakeholders. I’m convinced it will be a game changer for both clinicians and patients, and a step towards more equal and sustainable care.
The order intake and net sales declined organically by 5% and 2.6%, respectively, during the quarter. As a result of the overall uncertainty linked to these external factors, we are lowering our outlook for organic sales growth, which is expected to decrease by 3-6% for the full year 2022.
With Cardiohelp onboard, we offer people at age 18 to 50, who suffer from out-of-hospital cardiac arrest, a much greater chance at survival. Without this possibility, these patients literally wouldn’t survive.
There is nothing more satisfying than seeing a patient go home, knowing that you contributed to their recovery.
To support this business expansion, Getinge has invested in doubling our stent production capacity in order to provide all of our global customers with the devices needed to treat patients.
It was a small, silent, yet powerful electronic device that challenged conventional wisdom and instantly responded to changes in patient needs. The Servo Ventilator is not just an engineering marvel; it is a mindset intrinsic in our DNA.
Order intake and net sales declined organically by 5% and 7.5% respectively in the quarter, which however ended with increased order intake. Our customers are planning for a normal flu season in the second half of the year, which is expected to result in a recovery in ICU products.
Seeing the Flow-i in the room was a big comfort for me in a very difficult situation.
The global demand for meat is not slowing down and we need a long term solution where food production doesn’t harm animals nor the environment.
With this product launch, we want to be part of opening up the door to the future, supporting the exciting yet challenging pharma industry transition.
People are given responsibility and are inspired to dare to try new things. I think this means a lot to the company culture, the fact that all employees are so actively involved in the success.
With Vac-a-Scope, we now offer our customers a complete solution for endoscope reprocessing, in our aim to help fight HCAI and contribute to a more sustainable health care.
Every time we develop new endoscope reprocessing solutions we focus on delivering value to our customers while maintaining the highest levels of safety and efficacy. Our solutions are designed for consistency, accuracy and cost-effective operations and our updated ED-Flow is no exception.
Helping others makes me feel proud, needed and satisfied all at once. I am convinced that if you do good, then good will come to you.
With the acquisition of FLUOPTICS, we are opening a new chapter for our Surgical Workflows business by expanding into the field of advanced visualization and decision support for surgeons
Net sales declined by 6.4% and the order intake fell organically by 4.4% in the quarter. However, excluding the strong sales of ventilators in 2021, we had organic growth in both order intake and net sales. The order book grew 8% during the quarter and is 21% higher now than the same period in 2021, excluding currency fluctuations.
We are proud to be part of this initiative that helps patients and medical staff by ensuring the supply of critical equipment where it’s urgently needed.
In the new Experience Center, visitors get to explore our solutions in a real life setting and learn more about new and advanced technologies that can help improve health care and life science.
It’s an industry filled with challenges which means you are constantly moving forward. I love the pace, and it’s truly exciting to work with life-saving technologies.
We are excited to launch this solution that will save time and investments for our customers, and bring comfort to a wide range of patients.